{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
fludrocortisone acetate
to a specific field?
Status:
Investigational
Source:
INN:utreglutide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01479244: Phase 3 Interventional Completed Breast Cancer With Low to Intermediate HER2 Expression
(2011)
Source URL:
Class:
PROTEIN
Nelipepimut-S (formerly known as E75) is an immunogenic peptide from the HER2 protein that is highly expressed in breast cancer. The NeuVax™ (Galena, OR, USA) vaccine, nelipepimut-S plus granulocyte-macrophage colony-stimulating factor, is designed for the prevention of clinical recurrences in high risk, disease-free breast cancer patients. Nelipepimut-S is being developed by Sellas Life Sciences Group. When combined with the immunoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF), nelipepimut-S has been used as a vaccine that is capable of eliciting a robust anti-HER2 immune response. Early-phase clinical trials that enrolled women with node-positive or high-risk node-negative breast cancer who had been rendered disease free with standard of care therapy but were at risk for recurrence, demonstrated the vaccine to be safe with a suggestion of clinical benefit. Nelipepimut-S is currently being evaluated in a Phase III clinical trial.
Status:
Investigational
Source:
NCT04311697: Phase 2/Phase 3 Interventional Completed Critical COVID-19 With Respiratory Failure
(2020)
Source URL:
Class:
PROTEIN
Aviptadil, a vasoactive intestinal polypeptide, is a vasodilator and lowers blood pressure if administered intravenously. In 2007, the orphan designation was granted by the European Commission for aviptadil for the treatment of sarcoidosis, a disease of unknown cause that affects many organs and tissues, most commonly the lungs. Sarcoidosis is characterized by specific microscopic lesions called granulomas. Aviptadil is able to influence the immune system that decreases the inflammatory processes seen in sarcoidosis by acting on the white blood cells (lymphocytes and monocytes) involved in the formation of the granulomas. In combination with phentolamine, the drug is used to treat erectile dysfunction. In addition, aviptadil has been studied in phase II clinical trials for patients with respiratory distress syndrome.
Status:
Investigational
Source:
NCT00131482: Phase 2 Interventional Terminated Radius Fracture
(2004)
Source URL:
Class:
PROTEIN
Rusalatide acetate (also known as chrysalin or TP 508) is a 23-amino acid peptide derived from human prothrombin; it represents part of the receptor-binding domain of the human thrombin molecule. Rusalatide acetate binds to high-affinity thrombin receptors and mimics cellular effects of thrombin at sites of tissue injury. Rusalatide acetate demonstrated safety and potential efficacy in phase I/II clinical trials for the treatment of diabetic foot ulcers. It interacts with cell surface receptors to stimulate a cascade of cellular and molecular wound healing events, including activation of nitric oxide signaling. In addition, this drug participated in phase II clinical trial to determine the effectiveness of four doses for treating broken wrists in adults. However, this study was terminated because the drug did not demonstrate benefit compared to placebo. Rusalatide acetate was also studied as a cardiovascular drug. However, in January 2012, Capstone discontinued the development of rusalatide, for financial reasons. Recent studies show that a single injection of TP508 (rusalatide acetate) administered 24 h after irradiation significantly increases survival and delays mortality in murine models of acute radiation mortality. Thus, this drug is being developed as a potential nuclear countermeasure.
Status:
Investigational
Source:
NCT03395704: Phase 2 Interventional Completed Hereditary Hemochromatosis
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:etimumotide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00099580: Phase 2 Interventional Completed Congestive Heart Failure
(2005)
Source URL:
Class:
PROTEIN
AC-2592 (glucagon-like peptide 1, or GLP-1) was being in development by Amylin Pharmaceuticals for the treatment of severe congestive heart failure. AC-2592 is a glucagon like peptide 1 receptor agonist.
Status:
Investigational
Source:
NCT00259233: Not Applicable Interventional Completed Obesity
(2005)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01933256: Phase 1 Interventional Completed Type 2 Diabetes Mellitus
(2013)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01396213: Phase 2 Interventional Completed Celiac Disease
(2011)
Source URL:
Class:
PROTEIN
N-(2-Bromophenyl)-9-Methyl-9-Azabicyclo[3.3.1]Nonan-3-Amine (also known as AT-1001) is a high-affinity and highly selective ligand at α3β4 nicotinic cholinergic receptors (nAChRs) that was reported to decrease nicotine self-administration in rats. AT-1001 has a single-digit nanomolar binding affinity for the α3β4 nAChR and over 100-fold selectivity over the α4β2 nAChR and α7 nAChR in competition binding experiments. In electrophysiological experiments, AT-1001 had partial agonist activity at the α3β4 nAChR, evoking 35% of maximum ACh response, and at the same doses, produced desensitization of the ACh response, effectively acting as a functional antagonist at the α3β4 nAChR. Interestingly, AT-1001 also selectively decreased self-administration of cigarette smoke extract (CSE), an aqueous extract of cigarette smoke components, without altering natural food intake, when administered systemically to rats trained to self-administer CSE
